63 completed, 35 recruiting, 22 unknown, 14 terminated. 60 Phase 2, 24 Phase 1, 17 Not applicable, 6 Phase 3, 4 Phase 4.
Follow Paraganglioma: new trials by email Literature Review of Paraganglioma trials Research Report on Paraganglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| Zanzalintinib in Unresectable and Progressive MPGGs Zanzalintinib - Pheochromocytoma, Paraganglioma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 14 | 2027-01-09 | 2026-07-20 |
| 211At-MABG in Adults With Advanced Neuroendocrine Cancers 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated - Pheochromocytoma, Paraganglioma | Phase 1 | Not yet recruiting | University of Pennsylvania | 16 | 2026-12-01 | 2026-10-07 |
| A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT - Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma | Not yet recruiting | British Columbia Cancer Agency | 60 | 2026-11-30 | 2026-10-06 | |
| Comparison of an Initial Active Follow-up and Therapeutic Care on Functional Outcome and Quality of Life in Patients With Head and Neck Paragangliomas Active follow-up, Surgery, Radiation - Paragangliomas | Not applicable | Not yet recruiting | Hospices Civils de Lyon | 122 | 2026-10-10 | 2026-08-25 |
| Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT) Peptide Receptor Radionuclide Therapy (PRRT) - Pheochromocytomas, Paragangliomas | Not yet recruiting | Azienda USL Reggio Emilia - IRCCS | 210 | 2026-08-30 | 2026-07-17 | |
| An Experimental Study of Belzutifan Impact on Catecholamine Metabolism Belzutifan - Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant | Phase 2 | Recruiting | Cambridge University Hospitals NHS Foundation Trust | 12 | 2026-04-27 | 2026-07-02 |
| Prospective Cohort Study of Pheochromocytoma/Paraganglioma Pheochromocytoma, Paraganglioma | Not yet recruiting | Peking Union Medical College Hospital | 200 | 2026-04-01 | 2026-04-07 | |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma ONC206, ONC206: Dose 1, ONC206: Dose 2 - Advanced Pheochromocytoma and Paraganglioma, PCPG | Phase 2 | Recruiting | Jazz Pharmaceuticals | 90 | 2026-01-02 | 2026-10-02 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors adrenalectomy - Pheochromocytoma, Cardiovascular Complication | Recruiting | Central Hospital, Nancy, France | 522 | 2025-10-01 | 2026-10-22 | |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [18F]FAPI-74, [18F]FDG - Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-09-09 | 2026-05-19 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma Anlotinib and Benmelstobart - Pheochromocytoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 22 | 2025-05-01 | 2025-04-29 |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET - Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-02-07 | 2026-10-16 |
| National Study of Adrenal Tumours Pheochromocytoma and Paraganglioma (PPGL), Adrenocorticol Cancer (ACC) | Enrolling by invitation | Society for Endocrinology | 300 | 2025-01-15 | 2025-03-11 | |
| 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System 18F-mFBG - Neuroblastoma, Pheochromocytoma | Phase 2 | Withdrawn | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | 2025-01-01 | 2025-01-21 | |
| Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma Neuroblastoma, Pheochromocytoma | Recruiting | Nanjing First Hospital, Nanjing Medical University | 30 | 2024-12-25 | 2025-09-26 | |
| Ivonescimab in the Treatment of Multiple Advanced Tumors Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 400 | 2024-11-20 | 2025-08-24 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
Showing 20 of 172. Sign in to see all of them.
Pheochromocytoma (156) · Neuroendocrine Tumors (29) · Neuroblastoma (23) · Carcinoma, Medullary (17) · Adrenocortical Carcinoma (13) · Neoplasms (13) · Adrenal Gland Neoplasms (12) · Carcinoma, Renal Cell (12) · Neoplasm Metastasis (12) · Carcinoid Tumor (11) · Kidney Neoplasms (11) · Cushing Syndrome (10) · Hyperaldosteronism (10) · Insulinoma (10)
Neoplasms by Histologic Type (172) · Neoplasms, Germ Cell and Embryonal (172) · Neoplasms, Nerve Tissue (172) · Neuroectodermal Tumors (172) · Neoplasms (159) · Neuroendocrine Tumors (143) · Neoplasms, Glandular and Epithelial (69) · Neoplasms by Site (64) · Endocrine System Diseases (55) · Carcinoma (50) · Endocrine Gland Neoplasms (49) · Adenocarcinoma (47) · Neoplasms, Neuroepithelial (32) · Neuroectodermal Tumors, Primitive (29)
3-Iodobenzylguanidine (14) · Temozolomide (6) · lutetium Lu 177 dotatate (6) · Everolimus (5) · gallium Ga 68 dotatate (5) · Magnetic Resonance Spectroscopy (4) · anlotinib (4) · 3-fluorobenzylguanidine (3) · 6-fluorodopamine (3) · Doxorubicin (3) · Phenoxybenzamine (3) · Radiotherapy (3) · Specimen Handling (3) · belzutifan (3) · cabozantinib (3)
National Cancer Institute (NCI) (18) · Peking Union Medical College Hospital (11) · M.D. Anderson Cancer Center (5) · Molecular Insight Pharmaceuticals, Inc. (5) · Seoul National University Hospital (5) · British Columbia Cancer Agency (4) · University of California, San Francisco (4) · Hospices Civils de Lyon (3) · Jagiellonian University (3) · Radboud University Medical Center (3) · Asan Medical Center (2) · Assistance Publique - Hôpitaux de Paris (2) · Assistance Publique Hopitaux De Marseille (2) · Central Hospital, Nancy, France (2) · Children's Hospital Medical Center, Cincinnati (2)
United States (77) · China (20) · France (19) · Canada (11) · Netherlands (11) · United Kingdom (10) · Italy (8) · South Korea (8) · Spain (7) · Denmark (5) · Germany (5) · Poland (4) · Singapore (4) · Switzerland (4) · Sweden (3)
Anli Tong (6) · Frank I Lin, M.D. (3) · Camilo Jimenez (2) · Francois Benard, MD (2) · John W Glod, M.D. (2) · M. Sue O'Dorisio, MD, PhD (2) · A A. Franken, MD PhD (1) · A.N. Van Geel, MD (1) · Adrian Gadano, MD (1) · Afshin Shafie, MD (1) · Agustin Garcia (1) · Alice Lee, MD (1) · Allison Betof Warner, MD, PhD (1) · Andrea B Apolo, M.D. (1)
PMID 31714582, PMID 11996444, PMID 12192533, PMID 1732972, PMID 18626702, PMID 19636009, PMID 20546874, PMID 20847174, PMID 22136841, PMID 22954508, PMID 23554030, PMID 24571724, PMID 24939623, PMID 24952730, PMID 25243546, PMID 25456922, PMID 25900182, PMID 26040622, PMID 26742708, PMID 26773712, PMID 27389594, PMID 27561909, PMID 29099942, PMID 29138385, PMID 29149611, PMID 29168209, PMID 29189215, PMID 29534198, PMID 29962874, PMID 30624247, PMID 30976898, PMID 31057686, PMID 31231443, PMID 31322702, PMID 31533818, PMID 31969335, PMID 31985457, PMID 32184394, PMID 32188704, PMID 32303619, PMID 32534809, PMID 33362722, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33551992, PMID 33608270, PMID 33770291, PMID 33882143, PMID 34241781
2023 (2), P30CA015083 (2), 2019 (1), N01CM00039 (1), N01CM00099 (1), N01CM62205 (1), P30CA016672 (1), R01CA264248 (1), R01CA300202 (1), R01GM114102 (1), U01CA062461 (1), U01CA097452 (1), U10CA098543 (1), U10CA180821 (1), U10CA180886 (1)